{"id":"https://openalex.org/W2418224972","doi":null,"title":"Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge.","display_name":"Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge.","publication_year":1997,"publication_date":"1997-06-01","ids":{"openalex":"https://openalex.org/W2418224972","mag":"2418224972","pmid":"https://pubmed.ncbi.nlm.nih.gov/9379784"},"language":"en","primary_location":{"id":"pmid:9379784","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9379784","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Methods and findings in experimental and clinical pharmacology","raw_type":"Clinical Trial"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"V Jagannathan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"V Jagannathan","raw_affiliation_strings":["Department of Pharmacy and Pharmaceutics, Virginia Commonwealth University, Richmond, USA","Department of Pharmacy & Pharmaceutics, Virginia Commonwealth University, Richmond, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy and Pharmaceutics, Virginia Commonwealth University, Richmond, USA","institution_ids":["https://openalex.org/I184840846"]},{"raw_affiliation_string":"Department of Pharmacy & Pharmaceutics, Virginia Commonwealth University, Richmond, USA","institution_ids":["https://openalex.org/I184840846"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5030037733","display_name":"J\u00fcrgen Venitz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J Venitz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.31958763,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"19","issue":"5","first_page":"351","last_page":"62"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11337","display_name":"Tryptophan and brain disorders","score":0.7153000235557556,"subfield":{"id":"https://openalex.org/subfields/2803","display_name":"Biological Psychiatry"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11337","display_name":"Tryptophan and brain disorders","score":0.7153000235557556,"subfield":{"id":"https://openalex.org/subfields/2803","display_name":"Biological Psychiatry"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.1973000019788742,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.05820000171661377,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/buspirone","display_name":"buspirone","score":0.9430000185966492},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8479999899864197},{"id":"https://openalex.org/keywords/5-ht1a-receptor-agonist","display_name":"5-HT1A receptor agonist","score":0.8190000057220459},{"id":"https://openalex.org/keywords/prolactin","display_name":"prolactin","score":0.7559999823570251},{"id":"https://openalex.org/keywords/cortisol","display_name":"cortisol","score":0.9729999899864197},{"id":"https://openalex.org/keywords/subjective-rating-scales","display_name":"subjective rating scales","score":0.6470000147819519},{"id":"https://openalex.org/keywords/electroencephalography","display_name":"EEG","score":0.3959999978542328},{"id":"https://openalex.org/keywords/cognitive-function","display_name":"cognitive function","score":0.5519999861717224}],"concepts":[{"id":"https://openalex.org/C2777287423","wikidata":"https://www.wikidata.org/wiki/Q412194","display_name":"Buspirone","level":4,"score":0.9363631010055542},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.7585541009902954},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7058867812156677},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6605161428451538},{"id":"https://openalex.org/C2777765862","wikidata":"https://www.wikidata.org/wiki/Q62903","display_name":"Anxiolytic","level":3,"score":0.6396485567092896},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.551240861415863},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.5303324460983276},{"id":"https://openalex.org/C2776706248","wikidata":"https://www.wikidata.org/wiki/Q181003","display_name":"Tryptophan","level":3,"score":0.5181906819343567},{"id":"https://openalex.org/C76318530","wikidata":"https://www.wikidata.org/wiki/Q16833590","display_name":"Area under the curve","level":2,"score":0.5103225111961365},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.48016542196273804},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.4328407347202301},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.4213062822818756},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.4159639775753021},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3865809440612793},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.37109100818634033},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.36766594648361206},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3559170067310333},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.05588671565055847},{"id":"https://openalex.org/C515207424","wikidata":"https://www.wikidata.org/wiki/Q8066","display_name":"Amino acid","level":2,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002065","descriptor_name":"Buspirone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002065","descriptor_name":"Buspirone","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D002065","descriptor_name":"Buspirone","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D002065","descriptor_name":"Buspirone","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D002065","descriptor_name":"Buspirone","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D002490","descriptor_name":"Central Nervous System","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D003071","descriptor_name":"Cognition","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D004032","descriptor_name":"Diet","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004569","descriptor_name":"Electroencephalography","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006854","descriptor_name":"Hydrocortisone","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011388","descriptor_name":"Prolactin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D014151","descriptor_name":"Anti-Anxiety Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014151","descriptor_name":"Anti-Anxiety Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D014151","descriptor_name":"Anti-Anxiety Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D014364","descriptor_name":"Tryptophan","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D014364","descriptor_name":"Tryptophan","qualifier_ui":"Q000172","qualifier_name":"deficiency","is_major_topic":true},{"descriptor_ui":"D016037","descriptor_name":"Single-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017366","descriptor_name":"Serotonin Receptor Agonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D017366","descriptor_name":"Serotonin Receptor Agonists","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D017366","descriptor_name":"Serotonin Receptor Agonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:9379784","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9379784","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Methods and findings in experimental and clinical pharmacology","raw_type":"Clinical Trial"},{"id":"mag:2418224972","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9379784","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2069704104","https://openalex.org/W2051379110","https://openalex.org/W1972463582","https://openalex.org/W2567081643","https://openalex.org/W2126364883","https://openalex.org/W2021789728","https://openalex.org/W2108374655","https://openalex.org/W2040195745","https://openalex.org/W1981691052","https://openalex.org/W2065448957"],"abstract_inverted_index":{"This":[0,303],"study":[1,34,46,63,90,230,304,363],"was":[2,35,48,112,159,175,242],"designed":[3],"to":[4,85,142,188,318,350,364,400],"evaluate":[5],"the":[6,9,60,79,137,154,197,215,224,238,247,254,260,269,275,290,295,355,359,368,372,375,379,384,393,397],"relationship":[7],"between":[8],"pharmacokinetic(s)":[10],"(PK)":[11],"and":[12,101,110,124,127,150,163,184,211,253,286,288,314,323,329,402],"CNS":[13,301],"pharmacodynamic(s)":[14],"(PD)":[15],"of":[16,97,116,144,196,266,277,284,299,341,347,354,358,374],"buspirone,":[17,278],"an":[18,27],"antidepressant/anxiolytic,":[19],"in":[20,53,153,228,237,246,259,343,367,387],"6":[21],"healthy":[22,344],"male":[23],"volunteers":[24,345],"placed":[25],"on":[26],"acute":[28],"L-tryptophan":[29,140,156,167,177,185,321],"deficient":[30],"(ATD)":[31],"diet.":[32,199],"The":[33,44,133,148,333],"a":[36,49,243,311,339],"randomized,":[37],"double-blind,":[38],"placebo-controlled,":[39],"four-period,":[40],"three-way":[41],"crossover":[42],"study.":[43],"first":[45],"period":[47,52],"single-blind":[50],"familiarization":[51],"which":[54],"all":[55],"subjects":[56,65,93],"received":[57,66],"placebo.":[58],"During":[59],"remaining":[61],"three":[62],"periods,":[64],"either":[67],"placebo,":[68],"10":[69,225],"mg":[70,73,226],"or":[71],"30":[72],"oral":[74],"buspirone.":[75],"Subjects":[76],"were":[77,231,272,294],"administered":[78],"ATD":[80,134,173,198,308,334,376],"diets":[81],"5":[82,170],"h":[83,171,193],"prior":[84],"buspirone/placebo":[86],"administration":[87,195],"during":[88],"each":[89],"period.":[91],"All":[92],"underwent":[94],"serial":[95],"measurements":[96],"resting":[98],"electroencephalography":[99],"(REEG)":[100],"vigilance":[102],"electroence-phalography":[103],"(VEEG),":[104],"cognitive":[105,261],"tests,":[106],"subjective":[107,250,291,388],"rating":[108,251,292,389],"scales,":[109],"blood":[111],"sampled":[113],"for":[114,180,202,221],"determination":[115],"unbound":[117,138,155],"plasma":[118,125,139,208,216,282,320],"L-tryptophan,":[119],"serum":[120,122],"prolactin,":[121],"cortisol":[123],"buspirone":[126,203,222,285,401],"its":[128,348],"active":[129],"metabolite,":[130],"1-pyrimdylpiperazine":[131],"(1-PP).":[132],"diet":[135,174,309,377],"reduced":[136],"concentrations":[141,186,283,322],"20%":[143],"their":[145],"baseline":[146,189],"values.":[147],"intraindividual":[149],"interindividual":[151],"variability":[152],"concentration":[157,209],"drop":[158],"less":[160],"than":[161,233],"10%":[162],"15%,":[164],"respectively.":[165],"Peak":[166],"depletion":[168,178],"occurred":[169],"after":[172,194],"administered;":[176],"lasted":[179],"approximately":[181,191],"11":[182],"h,":[183],"recovered":[187],"values":[190],"13":[192],"PK-PD":[200],"analysis":[201],"showed":[204],"that:":[205],"1)":[206],"peak":[207],"(Cmax)":[210],"total":[212],"area":[213],"under":[214],"concentration-time":[217],"curve":[218],"(AUC":[219],"infinity)":[220],"following":[223],"dose":[227],"this":[229,362],"higher":[232],"those":[234,365],"reported":[235,366],"previously":[236],"literature;":[239],"2)":[240],"there":[241],"transient":[244,352],"response":[245],"neuroendocrine":[248,381],"measures,":[249],"scales":[252,293,390],"EEG,":[255],"but":[256,279],"no":[257],"changes":[258,386],"tests":[262],"with":[263,274,281],"increasing":[264],"doses":[265,276],"buspirone;":[267],"3)":[268],"PD":[270],"measures":[271],"correlated":[273],"not":[280],"1-PP;":[287],"4)":[289],"most":[296],"sensitive":[297],"indicators":[298],"buspirone's":[300],"effects.":[302],"provides":[305],"evidence":[306],"that":[307,371],"is":[310],"simple,":[312],"specific":[313],"non-toxic":[315],"experimental":[316],"method":[317],"lower":[319],"thereby":[324],"(indirectly)":[325],"deplete":[326],"brain":[327],"tryptophan":[328],"serotonin":[330],"(5-HT)":[331],"concentrations.":[332],"challenge":[335],"may":[336],"serve":[337],"as":[338],"model":[340],"depression":[342],"because":[346],"ability":[349],"induce":[351],"symptoms":[353],"disease.":[356],"Comparison":[357],"results":[360],"from":[361],"literature":[369],"suggests":[370],"use":[373],"decreases":[378],"buspirone-induced":[380,385],"response,":[382],"increases":[383,396],"and,":[391],"at":[392],"same":[394],"time,":[395],"systemic":[398],"exposure":[399],"1-PP.":[403]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}